Published online Apr 16, 2023. doi: 10.12998/wjcc.v11.i11.2435
Peer-review started: January 5, 2023
First decision: January 30, 2023
Revised: February 7, 2023
Accepted: March 23, 2023
Article in press: March 23, 2023
Published online: April 16, 2023
Isotretinoin is a widely prescribed medication for various dermatological conditions, particularly acne. Regular blood tests are performed to monitor its side effects. However, the optimal tests and their timing remain controversial.
Since 2006, many studies have reported that only a small proportion of patients taking isotretinoin have abnormal laboratory test results. Thus, frequent monitoring of isotretinoin treatment may be unnecessary.
This study aimed to evaluate the most efficient testing regimen for patients with acne taking isotretinoin.
This retrospective study analyzed medical records obtained from Dongguk University Ilsan Hospital’s electronic medical records database. Independent variables (e.g., sex, total prescription date and dose, daily average prescription dose, underlying disease type, and monthly interval per blood test) were analyzed using repeated-measures analysis of variance.
Aspartate aminotransferase, alanine aminotransferase, and triglyceride levels significantly changed between 5 and 6 mo when the total prescription period and dose variables were considered altogether. High-density lipoprotein level also significantly changed between 5 and 6 mo. However, low-density lipoprotein and total cholesterol levels significantly changed between 1 and 2 mo.
Liver and lipid panel should be performed before beginning isotretinoin administration, 1 and 2 mo after administration, and every 6 mo thereafter if no abnormalities are detected to save on costs.
This article will contribute to Asian-specific isotretinoin laboratory guidelines and further studies.